Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)


Phase III, Multi-Center, Study to Assess the Clinical Effect of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic NOH




The purpose of this study is to see whether droxidopa is effective in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy, Parkinson`s Disease), Non-diabetic neuropathy, or Beta Hydroxylase deficiency.

Study Status: Completed


Condition Intervention Phase
Symptomatic Neurogenic Orthostatic Hypotension (NOH)
Non-diabetic Neuropathy
Primary Autonomic Failure
Dopamine Beta Hydroxylase Deficiency
Drug: Placebo
Drug: Droxidopa
Phase 3

Verified by Chelsea Therapeutics March, 2013

Sponsored by: Chelsea Therapeutics
Information provided by: Chelsea Therapeutics identifier: NCT00633880

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio 44195
United States

Horacio Kaufmann, MD., Principal Investigator
Christopher J Mathias, MD., Principal Investigator
Roy Freeman, MD., Principal Investigator
Phillip A Low, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site